Insulin price cuts could end up making money for US drugmakers
Potentially avoiding paying multimillion-dollar rebates to US healthcare program Medicare, Novo Nordisk and Eli Lilly could actually increase profits by slashing insulin prices.
By Ilena Peng and Emma Court, bloomberg
The world’s biggest makers of insulin are likely to make more money, not less, even after slashing prices by as much as 75% due to US government pressure.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Joe Biden applauds Novo Nordisk for insulin price reductions
For subscribers
Novo Nordisk to reduce insulin prices by up to 75% in the US
For subscribers
.jpg&w=384&q=75)
